The Latest Breaking News from FDA

Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for Vurolenatide in short bowel syndrome.

Gainers

Tesla CEO insists the recent problem with its car windows is merely a patch. Who is right?

We only recommend products we love and that we think you will, too. We may receive a portion of sales from products purchased from this article, which was written by our Commerce team.

Bloomberg

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back…

Ketamine is becoming a mainstream in the world of mental health and a slew of new research suggests it has real potential to treat conditions like depression.

Suzan Kennedy has smoked marijuana, and says her Wisconsin roots mean she can handle booze, so she was not concerned earlier this year when a bartender in St. Paul, Minnesota, described a cocktail with the cannabinoid delta-8 THC as “a little bit potent.”

BOSTON — Eight years after the ALS Ice Bucket Challenge went viral across social media and raised hundreds of millions of dollars for research, a Cambridge company is on the brink of a major breakthrough for ALS patients.

S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market.

TikTok searches soared amid flood of media coverage, raising questions about the response to extreme social media challenges